{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:31:13Z","timestamp":1784543473126,"version":"3.55.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Adenosine deaminase 2 deficiency (DADA-2) is an autoinflammatory syndrome caused by mutations in the <jats:italic>ADA2<\/jats:italic> gene. ADA-2 functions as an enzyme in purine metabolism and is presumed to play roles in immune regulation. The clinical spectrum of DADA2varies widely, from vascular inflammation and immune dysregulation to hematological abnormalities, including pure red cell aplasia and hemophagocytic lymphohistiocytosis (HLH). This study aimed to describe the clinical, demographic, and immunological profiles of seven DADA-2 patients to broaden the understanding of its hematological and immunological manifestations and provide insight for early diagnosis and treatment strategies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were collected from patient medical records at the Department of Pediatric Allergy and Clinical Immunology, Basaksehir Cam and Sakura City Hospital. The study included genetic analysis, flow cytometry for lymphocyte subpopulations, and ADA-2 enzyme activity measurement.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seven patients from five families were included, predominantly male, with an average symptom onset at 15 months. Hematological findings were present in all patients, with neutropenia observed at the initial presentation (100%). HLH developed in two patients, contributing to a higher mortality rate of 42.8%. Bone marrow analysis in affected patients revealed hypocellularity and marked T-cell infiltration, with fibrosis detected in one. Despite no evidence of viral triggers (EBV, CMV, VZV, Parvovirus B19), HLH occurred in two patients, suggesting a primary immune dysregulation. Inflammatory and immunodeficiency-related findings were also observed, suggesting a mixed phenotype as the most common presentation. Genotype-phenotype analysis showed that patients with undetectable ADA2 enzyme activity or loss-of-function mutations had more severe hematological involvement. In contrast, a patient with residual enzyme activity exhibited a mixed phenotype. Three patients underwent successful hematopoietic stem cell transplantation (HSCT), reversing disease manifestations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings reinforce that DADA2 can initially present as isolated neutropenia, and frequently exhibits a mixed phenotype encompassing hematologic, immunologic, and inflammatory features. HLH is a severe complication that may arise without infectious triggers. Genetic testing for <jats:italic>ADA2<\/jats:italic> should be incorporated into diagnostic panels for congenital neutropenia to avoid delays in diagnosis. Genotype\u2013phenotype correlations offer some prognostic insights, but residual enzyme activity may not fully predict disease severity, underscoring the need for individualized management.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1639318","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T05:31:50Z","timestamp":1759383110000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Early-onset neutropenia and mixed phenotype in ADA2 deficiency: diagnostic and therapeutic challenges"],"prefix":"10.3389","volume":"16","author":[{"given":"Sibel","family":"Kaplan Sar\u0131kavak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zge","family":"T\u00fcrky\u0131lmaz U\u00e7ar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"Cil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Hershfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa K.","family":"Tarrant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinar","family":"G\u00f6kmirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c7i\u011fdem","family":"Aydo\u011fmus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1307361","article-title":"Early-onset stroke and vasculopathy associated with mutations in ADA2","volume":"370","author":"Zhou","year":"2014","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1109764","article-title":"Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages","volume":"88","author":"Zavialov","year":"10","journal-title":"J Leukoc Biol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-016-2357-0","article-title":"Human adenosine deaminases ADA1 and ADA2 bind to different subsets of immune cells","volume":"74","author":"Kaljas","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aba3688","article-title":"Cellular sensing of extracellular purine nucleosides triggers an innate IFN-\u03b2 response","volume":"6","author":"Dhanwani","year":"2020","journal-title":"Sci Adv"},{"key":"B5","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1182\/blood.2018892752","article-title":"Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2","volume":"134","author":"Carmona-Rivera","year":"2019","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-022-00918-8","article-title":"Mechanisms of vascular inflammation in deficiency of adenosine deaminase 2 (DADA2)","volume":"44","author":"Lee","year":"2022","journal-title":"Semin Immunopathol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-024-01163-9","article-title":"Human ADA2 deficiency: ten years later","volume":"24","author":"Wouters","year":"2024","journal-title":"Curr Allergy Asthma Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.937108","article-title":"Case Report: Susceptibility to viral infections and secondary hemophagocytic lymphohistiocytosis responsive to intravenous immunoglobulin as primary manifestations of adenosine deaminase 2 deficiency","volume":"13","author":"Drago","year":"2022","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-023-01521-8","article-title":"Clinical symptoms, laboratory parameters and long-term follow-up in a national DADA2 cohort","volume":"43","author":"Andriessen","year":"2023","journal-title":"J Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.15894","article-title":"Evaluation and management of deficiency of adenosine deaminase 2: an international consensus statement","volume":"6","author":"Lee","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181384","article-title":"A monogenic disease with a variety of phenotypes: deficiency of adenosine deaminase 2","volume":"47","author":"\u00d6zen","year":"2020","journal-title":"J Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-021-01098-0","article-title":"Hematopoietic cell transplantation cures adenosine deaminase 2 deficiency: report on 30 patients","volume":"41","author":"Hashem","year":"2021","journal-title":"J Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.811473","article-title":"The spectrum of the deficiency of adenosine deaminase 2: an observational analysis of a 60 patient cohort","volume":"12","author":"Barron","year":"2021","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.869570","article-title":"Deficiency of human adenosine deaminase type 2 - A diagnostic conundrum for the hematologist","volume":"13","author":"Pilania","year":"2022","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.jaci.2019.12.908","article-title":"Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2)","volume":"145","author":"Lee","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3906\/sag-2010-176","article-title":"Reference values for T and B lymphocyte subpopulations in Turkish children and adults","volume":"51","author":"Besci","year":"2021","journal-title":"Turk J Med Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3906\/sag-1807-282","article-title":"Reference ranges for serum immunoglobulin (IgG, IgA, and IgM) and IgG subclass levels in healthy children","volume":"49","author":"Bayram","year":"2019","journal-title":"Turk J Med Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05711-w","article-title":"Expanding spectrum of DADA2: a review of phenotypes, genetics, pathogenesis and treatment","volume":"40","author":"Pinto","year":"2021","journal-title":"Clin Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-020-00817-3","article-title":"Deficiency of adenosine deaminase 2 (DADA2): hidden variants, reduced penetrance, and unusual inheritance","volume":"40","author":"Schnappauf","year":"2020","journal-title":"J Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.910021","article-title":"Case Report: Consistent disease manifestations with a staggered time course in two identical twins affected by adenosine deaminase 2 deficiency","volume":"13","author":"Barzaghi","year":"2022","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13023-023-02721-6","article-title":"A wide spectrum of phenotype of deficiency of deaminase 2 (DADA2): a systematic literature review","volume":"18","author":"Maccora","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/08820139.2020.1853153","article-title":"Adenosine deaminase type II deficiency: severe chronic neutropenia, lymphoid infiltration in bone marrow, and inflammatory features","volume":"51","author":"S\u00fcleyman","year":"2022","journal-title":"Immunol Invest"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1177\/23247096211056770","article-title":"Novel adenosine deaminase 2 (ADA2) mutations associated with hematological manifestations","volume":"9","author":"Albalawi","year":"2021","journal-title":"J Investig Med High Impact Case Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jaci.2016.03.016","article-title":"Adenosine deaminase type 2 deficiency masquerading as GATA2 deficiency: Successful hematopoietic stem cell transplantation","volume":"138","author":"Hsu","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29461","article-title":"DADA2 presenting as nonimmune hemolytic anemia with recurrent macrophage activation syndrome","volume":"69","author":"Iyengar","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-023-01555-y","article-title":"A narrative review of the neurological manifestations of human adenosine deaminase 2 deficiency","volume":"43","author":"Dzhus","year":"2023","journal-title":"J Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-021-01141-0","article-title":"Intrinsic defects in B cell development and differentiation, T cell exhaustion and altered unconventional T cell generation characterize human adenosine deaminase type 2 deficiency","volume":"41","author":"Yap","year":"2021","journal-title":"J Clin Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.jaci.2018.01.012","article-title":"ADA2 deficiency: Clonal lymphoproliferation in a subset of patients","volume":"141","author":"Trotta","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/art.40147","article-title":"Screening of 181 patients with antibody deficiency for deficiency of adenosine deaminase 2 sheds new light on the disease in adulthood","volume":"69","author":"Schepp","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.932385","article-title":"Allogeneic hematopoietic cell transplantation for patients with deficiency of adenosine deaminase 2 (DADA2): approaches, obstacles and special considerations","volume":"13","author":"Hashem","year":"2022","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1639318\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T05:31:51Z","timestamp":1759383111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1639318\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2025.1639318"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1639318","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"article-number":"1639318"}}